

## **Combining Focused Antisense Screening Technology (FAST) and Structure-based Drug Design (SBDD) for Antibacterial Discovery**

**Mark Stidham, Ph.D., Senior Director of Drug Discovery, Rx<sup>3</sup> Pharmaceuticals, San Diego, CA**

Application of mode of action and target structure information has enabled Rx<sup>3</sup> Pharmaceuticals to discover several innovative antibacterial leads. Focused antisense allows selection of on-target screening hits while SBDD allows simultaneous optimization for potency, spectrum, and drug properties. Using FAST and SBDD in tandem, we have three programs with strong profiles, including potent on-target antibacterial activity and drug-like properties.